| Endothelial destabilization by angiopoietin-2 via integrin β1 activation L Hakanpaa, T Sipila, VM Leppanen, P Gautam, H Nurmi, G Jacquemet, ... Nature communications 6 (1), 5962, 2015 | 269 | 2015 |
| Long-term ERK inhibition in KRAS-mutant pancreatic cancer is associated with MYC degradation and senescence-like growth suppression TK Hayes, NF Neel, C Hu, P Gautam, M Chenard, B Long, M Aziz, ... Cancer cell 29 (1), 75-89, 2016 | 229 | 2016 |
| Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer GA Hobbs, NM Baker, AM Miermont, RD Thurman, M Pierobon, TH Tran, ... Cancer discovery 10 (1), 104-123, 2020 | 153 | 2020 |
| KRAS suppression-induced degradation of MYC is antagonized by a MEK5-ERK5 compensatory mechanism AV Vaseva, DR Blake, TSK Gilbert, S Ng, G Hostetter, SH Azam, ... Cancer cell 34 (5), 807-822. e7, 2018 | 142 | 2018 |
| Drug target commons: a community effort to build a consensus knowledge base for drug-target interactions J Tang, B Ravikumar, Z Alam, A Rebane, M Vähä-Koskela, G Peddinti, ... Cell chemical biology 25 (2), 224-229. e2, 2018 | 127 | 2018 |
| Prediction of drug combination effects with a minimal set of experiments A Ianevski, AK Giri, P Gautam, A Kononov, S Potdar, J Saarela, ... Nature machine intelligence 1 (12), 568-577, 2019 | 118 | 2019 |
| Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma C Nepal, CJ O'Rourke, DVNP Oliveira, A Taranta, S Shema, P Gautam, ... Hepatology 68 (3), 949-963, 2018 | 117 | 2018 |
| Risk of handling paper currency in circulation chances of potential bacterial transmittance J Lamichhane, S Adhikary, P Gautam, R Maharjan, B Dhakal Nepal Journal of Science and Technology 10, 161-166, 2009 | 106 | 2009 |
| Bioluminescent, nonlytic, real-time cell viability assay and use in inhibitor screening SJ Duellman, W Zhou, P Meisenheimer, G Vidugiris, JJ Cali, P Gautam, ... Assay and drug development technologies 13 (8), 456-465, 2015 | 101 | 2015 |
| Consistency in drug response profiling JP Mpindi, B Yadav, P Östling, P Gautam, D Malani, A Murumägi, ... Nature 540 (7631), E5-E6, 2016 | 95 | 2016 |
| Low-dose vertical inhibition of the RAF-MEK-ERK cascade causes apoptotic death of KRAS mutant cancers I Ozkan-Dagliyan, JN Diehl, SD George, A Schaefer, B Papke, ... Cell reports 31 (11), 2020 | 75 | 2020 |
| Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects H Julkunen, A Cichonska, P Gautam, S Szedmak, J Douat, T Pahikkala, ... Nature communications 11 (1), 6136, 2020 | 72 | 2020 |
| Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells P Gautam, L Karhinen, A Szwajda, SK Jha, B Yadav, T Aittokallio, ... Molecular cancer 15, 1-16, 2016 | 70 | 2016 |
| Rational polypharmacology: systematically identifying and engaging multiple drug targets to promote axon growth H Al-Ali, DH Lee, MC Danzi, H Nassif, P Gautam, K Wennerberg, ... ACS chemical biology 10 (8), 1939-1951, 2015 | 70 | 2015 |
| Donor simvastatin treatment prevents ischemia-reperfusion and acute kidney injury by preserving microvascular barrier function R Tuuminen, AI Nykänen, P Saharinen, P Gautam, MAI Keränen, ... American Journal of Transplantation 13 (8), 2019-2034, 2013 | 56 | 2013 |
| Phenotypic screening combined with machine learning for efficient identification of breast cancer-selective therapeutic targets P Gautam, A Jaiswal, T Aittokallio, H Al-Ali, K Wennerberg Cell chemical biology 26 (7), 970-979. e4, 2019 | 38 | 2019 |
| CIP2A interacts with TopBP1 and drives basal-like breast cancer tumorigenesis A Laine, SG Nagelli, C Farrington, U Butt, AN Cvrljevic, JP Vainonen, ... Cancer research 81 (16), 4319-4331, 2021 | 32 | 2021 |
| A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening A Gupta, P Gautam, K Wennerberg, T Aittokallio Communications biology 3 (1), 42, 2020 | 30 | 2020 |
| Concurrent inhibition of IGF1R and ERK increases pancreatic cancer sensitivity to autophagy inhibitors CA Stalnecker, KR Grover, AC Edwards, MF Coleman, R Yang, ... Cancer research 82 (4), 586-598, 2022 | 28 | 2022 |
| Patient-tailored design for selective co-inhibition of leukemic cell subpopulations A Ianevski, J Lahtela, KK Javarappa, P Sergeev, BR Ghimire, P Gautam, ... Science advances 7 (8), eabe4038, 2021 | 28 | 2021 |
Tero AittokallioUniversity of Helsinki, University of Turku, University of OsloGeverifieerd e-mailadres voor utu.fi
